bioRxivBioengineeringPreprint
Facile Accelerated Specific Therapeutic (FAST) Platform to Counter Multidrug-Resistance Bacteria
K. A. Eller, T. R. Aunins, C. M. Courtney, J. K. Campos, P. B. Otoupal, K. E. Erickson, N. E. Madinger, A. Chatterjee
Abstract
Multidrug-resistant (MDR) bacteria pose a grave concern to global health. This problem is further aggravated by a lack of new and effective antibiotics and countermeasure platforms that can sustain the creation of novel antimicrobials in the wake of new outbreaks or evolution of resistance to antibiotics. To address this, we have developed a Facile Accelerated Specific Therapeutic (FAST) platform that can develop effective therapies against MDR bacteria within a week. Our FAST platform combines four essential modules- design, build, test, and delivery-of drug development cycle. The design module comprises a bioinformatics toolbox that predicts sequence-specific peptide nucleic acids (PNAs) that target non-traditional pathways and genes of bacteria in minutes. The build module constitutes in-situ synthesis and validation of selected PNAs in less than four days and efficacy testing within a day. As a proof of concept, these PNAs were tested against MDR clinical isolates. Here we tested Enterobacteriaceae including carbapenem-resistant Escherichia coli, extended-spectrum beta-lactamase (ESBL) Klebsiella pneumoniae, New Delhi Metallo-beta-lactamase-1 carrying Klebsiella pneumoniae and MDR Salmonella enterica. PNAs showed significant growth inhibition for 82% of treatments, with nearly 18% of the treatments leading to more than 97% decrease. Further, these PNAs are capable of potentiating antibiotic activity in the clinical isolates despite presence of cognate resistance genes. Finally, FAST offers a novel delivery approach to overcome limited transport of PNAs into mammalian cells to clear intracellular infections. This method relies on repurposing the bacterial Type III secretion system in conjunction with a kill switch that is effective at eliminating 99.6% of an intracellular Salmonella infection in human epithelial cells. Our findings demonstrate the potential of the FAST platform in treating MDR bacteria in a rapid and effective manner.
- organism: bacteria (other)
- assay: proteomics
- research focus: drug response / drug discovery
- approach: deep learning
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A novel broad-spectrum antibiotic targets multiple-drug-resistant bacteria with dual binding targets and no detectable resistance
Wenyan He, Xueting Huan, … Zongqiang Wang·Nature CommunicationsPeer-reviewed·Jul 31, 2025
- A Drug-free, Self-destruction Strategy to Combat Bacterial Infections by Using the Intrinsically formed Magnetic Nanoparticles in Bacterial Pathogens
D. Ghosh, S. Kaushik, … V. Gautam·bioRxiv·Feb 3, 2021
- A Triple-Modality Peptide-Antibiotic-Phage Therapy Eradicates Multidrug-Resistant Serratia marcescens Biofilms
Aryaan P. Duggal, Adit B. Alreja, … Norberto González-Juarbe·bioRxiv·Apr 9, 2026
- Potentiating antibiotic treatment using fitness-neutral gene expression perturbations
Peter B. Otoupal, Keesha E. Erickson, … Anushree Chatterjee·bioRxiv·Aug 15, 2019
- Tracking of antibiotic resistance transfer and rapid plasmid evolution in a hospital setting by Nanopore sequencing
Silke Peter, Mattia Bosio, … Stephan Ossowski·mSpherePeer-reviewed·Aug 18, 2020
- Evaluation of the novel culture-based FAST-T system allowing selection of optimal antibiotics for critically ill patients within 4 h (for other than bloodstream infectious).